F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
(2012) In Blood 119(12). p.2922-2934- Abstract
- This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development. Asystematic literature search was performed to include cohort studies published in peer-reviewed journals with data on inhibitor incidences in the various F8 gene mutation types and a mutation detection rate of at least 80%. Pooled odds ratios (ORs) of inhibitor development for different types of F8 gene mutations were calculated with intron 22 inversion as the reference. Data were included from 30 studies on 5383 patients, including 1029 inhibitor... (More)
- This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development. Asystematic literature search was performed to include cohort studies published in peer-reviewed journals with data on inhibitor incidences in the various F8 gene mutation types and a mutation detection rate of at least 80%. Pooled odds ratios (ORs) of inhibitor development for different types of F8 gene mutations were calculated with intron 22 inversion as the reference. Data were included from 30 studies on 5383 patients, including 1029 inhibitor patients. The inhibitor risk in large deletions and nonsense mutations was higher than in intron 22 inversions (pooled OR = 3.6, 95% confidence interval [95% CI], 2.3-5.7 and OR = 1.4, 95% CI, 1.1-1.8, respectively), the risk in intron 1 inversions and splice-site mutations was equal (pooled OR = 0.9; 95% CI, 0.6-1.5 and OR = 1.0; 95% CI, 0.6-1.5), and the risk in small deletions/insertions and missense mutations was lower (pooled OR = 0.5; 95% CI, 0.4-0.6 and OR = 0.3; 95% CI, 0.2-0.4, respectively). The relative risks for developing high titer inhibitors were similar. (Blood. 2012;119(12):2922-2934) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2591105
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 119
- issue
- 12
- pages
- 2922 - 2934
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000302121700030
- scopus:84863419863
- pmid:22282501
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2011-09-379453
- language
- English
- LU publication?
- yes
- id
- 3a98e5f3-947a-4da0-b6ef-461e2fbdb65f (old id 2591105)
- date added to LUP
- 2016-04-01 10:48:33
- date last changed
- 2022-04-12 17:39:50
@article{3a98e5f3-947a-4da0-b6ef-461e2fbdb65f, abstract = {{This systematic review was designed to provide more precise effect estimates of inhibitor development for the various types of F8 gene mutations in patients with severe hemophilia A. The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development. Asystematic literature search was performed to include cohort studies published in peer-reviewed journals with data on inhibitor incidences in the various F8 gene mutation types and a mutation detection rate of at least 80%. Pooled odds ratios (ORs) of inhibitor development for different types of F8 gene mutations were calculated with intron 22 inversion as the reference. Data were included from 30 studies on 5383 patients, including 1029 inhibitor patients. The inhibitor risk in large deletions and nonsense mutations was higher than in intron 22 inversions (pooled OR = 3.6, 95% confidence interval [95% CI], 2.3-5.7 and OR = 1.4, 95% CI, 1.1-1.8, respectively), the risk in intron 1 inversions and splice-site mutations was equal (pooled OR = 0.9; 95% CI, 0.6-1.5 and OR = 1.0; 95% CI, 0.6-1.5), and the risk in small deletions/insertions and missense mutations was lower (pooled OR = 0.5; 95% CI, 0.4-0.6 and OR = 0.3; 95% CI, 0.2-0.4, respectively). The relative risks for developing high titer inhibitors were similar. (Blood. 2012;119(12):2922-2934)}}, author = {{Gouw, Samantha C. and van den Berg, H. Marijke and Oldenburg, Johannes and Astermark, Jan and de Groot, Philip G. and Margaglione, Maurizio and Thompson, Arthur R. and van Heerde, Waander and Boekhorst, Jorien and Miller, Connie H. and le Cessie, Saskia and van der Bom, Johanna G.}}, issn = {{1528-0020}}, language = {{eng}}, number = {{12}}, pages = {{2922--2934}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis}}, url = {{http://dx.doi.org/10.1182/blood-2011-09-379453}}, doi = {{10.1182/blood-2011-09-379453}}, volume = {{119}}, year = {{2012}}, }